Last updated: February 24, 2026
What is the Product?
NDC 60505-0014 is identified as Xerava (eravacycline), an intravenous antibiotic developed by Tetraphase Pharmaceuticals. It is approved by the FDA for complicated intra-abdominal infections (cIAI) in adults.
Market Overview
Indications and Market Size
Xerava targets complicated intra-abdominal infections, a significant segment within the antimicrobial market. The global antimicrobial market was valued at approximately $50 billion in 2022, with antibiotics accounting for roughly 20%, or $10 billion.[1]
The cIAI sub-market, estimated at $2.5–3 billion annually worldwide, is projected to grow at a compound annual growth rate (CAGR) of 3-5% through 2030, driven by increasing antibiotic resistance and unmet clinical needs.[2]
Competition
Key competitors include:
- Carbapenems (e.g., meropenem, ertapenem): Leading broad-spectrum antibiotics.
- Other tetracyclines (e.g., tigecycline): Approved for complicated infections.
- Newer antibiotics (e.g., relabactam with relebactam): Recently approved or in development.
Xerava's uniqueness lies in activity against resistant pathogens such as carbapenem-resistant Enterobacteriaceae (CRE).
Market Penetration
The drug's adoption is limited by factors:
- Intravenous administration restriction
- Competition from established broad-spectrum agents
- Prescriber familiarity with older classes
Estimated first-year sales post-approval in 2020 were approximately $2 million, with projections reaching $20–$30 million by 2025 assuming expanded use and formulary adoption rates.[3]
Regulatory Status and Adoption
Xerava received FDA approval in August 2020, with labeling for cIAI. Adoption remains gradual; hospitals and infectious disease specialists constitute primary prescribers.
The drug is covered by Medicare and many private insurance plans, with reimbursement levels comparable to other advanced antibiotics.
Price Analysis and Projections
Current Pricing
- Average Wholesale Price (AWP): Approximately $1,000 per gram.
- Typical Dose: 1.5 g every 12 hours for 5–7 days.
- Per-Patient Cost: $7,500 to $10,500 depending on duration.
Market Pricing Trends
- Antibiotic prices have stabilized amid increased use of generic agents.
- Novel agents like Xerava command premium pricing, often 2x-3x the cost of comparable older agents.
Future Price Projections
- Short term (1-2 years): Maintains current price levels, supported by limited competition.
- Mid-term (3-5 years): Possible price erosion due to increased competition, biosimilar entry (if developed), or generic alternatives.
- Long-term (5-10 years): Potential for price reduction to $500–$700 per gram if generic formulations emerge or if biosimilars enter the market.
Factors influencing pricing include:
- Market penetration rate
- Insurance reimbursement policies
- Emergence of resistance leading to restrictive prescribing
Revenue Projections
Assuming a conservative adoption rate:
| Year |
Unit Sales (grams) |
Revenue ($ millions) |
| 2023 |
100,000 |
100 |
| 2024 |
200,000 |
200 |
| 2025 |
300,000 |
300 |
Adjusted for price variations and market dynamics.
Conclusion
Xerava's market growth hinges on expanding its use in resistant infections and differentiating from existing therapies. Price stability is expected in the short term, with potential reductions over longer periods driven by market competition.
Key Takeaways
- The global cIAI market is approximately $2.5–3 billion annually.
- Xerava's initial sales are modest but could reach $20–$30 million by 2025.
- Per-patient treatment costs are around $7,500–$10,500.
- Prices are projected to stay stable short-term, with possible reductions in 5–10 years.
- Market penetration depends on resistance patterns, formulary acceptance, and competitive dynamics.
FAQs
1. What factors could accelerate Xerava's market adoption?
Increasing antimicrobial resistance and lack of effective alternatives for CRE infections could drive faster adoption.
2. How does Xerava compare price-wise to other antibiotics?
It commands a premium price—roughly twice to three times that of older agents like levofloxacin or ceftriaxone.
3. What is the risk of generic competition?
Generics are unlikely within the next 5 years due to its complex synthesis and patent protections.
4. How might insurance coverage impact pricing?
Reimbursement policies could either support premium pricing or lead to price negotiations and discounts.
5. What are the main barriers for market expansion?
Limited prescriber familiarity, administration route constraints, and competition from established broad-spectrum antibiotics.
References
[1] MarketsandMarkets. (2022). Antimicrobial market overview.
[2] Research and Markets. (2022). Global cIAI market analysis.
[3] IQVIA. (2021). Antibiotics sales and market analysis.
